Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients

Cancer Research

Volumn 70, Issue 23, 2010, Pages 9721-9729

  Wu, Chen ^a   Xu, Binghe ^a   Yuan, Peng ^a   Miao, Xiaoping ^b   Liu, Yu ^a   Guan, Yin ^a   Yu, Dianke ^a   Xu, Jian ^a   Zhang, Tongwen ^a   Shen, Hongbing ^c   Wu, Tangchun ^b   Lin, Dongxin ^a  

^a CANCER HOSPITAL   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; TRANSCRIPTION FACTOR YAP1;

ADULT; ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMICAL ANALYSIS; CHROMOSOME 11Q; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; QUALITY CONTROL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TREATMENT RESPONSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COHORT STUDIES; ETOPOSIDE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 78649929368     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1493     Document Type: Article

References (23)

1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44. (Pubitemid 46630948)
2. Devesa SS, Shaw GL, Blot WJ. Changing patterns of lung cancer incidence by histological type. Cancer Epidemiol Biomarkers Prev 1991;1:29-34.
3. Simon G, Ginsberg RJ, Ruckdeschel JC. Small-cell lung cancer. Chest Surg Clin N Am 2001;11:165-88.
4. Simon GR, Wagner H. Small cell lung cancer. Chest 2003;123(1 Suppl):259S-71S.
5. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-96.
6. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
7. Chen J, Jiang R, Garces YI, Jatoi A, Stoddard SM, Sun Z, et al. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer 2006;67:221-6.
8. Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. J Am Med Assoc 2009;301:393-403.
9. Huang YT, Heist RS, Chirieac LR, Lin X, Skaug V, Zienolddiny S, et al. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol 2009;27:2660-7.
10. Landers JE, Melki J, Meininger V, Glass JD, van den Berg LH, van Es MA, et al. Reduced expression of the Kinesin-associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2009;106:9004-9.
11. Wu C, Xu B,Yuan P, Ott J,GuanY, LiuY, et al.Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer. Pharmacogenet Genom 2010;20:389-95.
12. Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001;25:409-18. (Pubitemid 34164013)
13. Baldwin C, Garnis C, Zhang L. Multiple microalterations detec ted at high frequency in oral cancer. Cancer Res 2005;65:7561-7. (Pubitemid 41297225)
14. Bashyam MD, Bair R, Kim YH, Wang P, Hernandez-Boussard T, Karikari CA, et al. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia 2005;7:556-62. (Pubitemid 40967756)
15. Lambros MB, Fiegler H, Jones A, Gorman P, Roylance RR, Carter NP, et al. Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization. J Pathol 2005;205:29-40. (Pubitemid 40029090)
16. Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, Jordan RC, et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 2005;24:4232-42. (Pubitemid 40961777)
17. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006;125:1253-67.
18. Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008;15:1752-9.
19. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 2001;276:15164-73.
20. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell 2005;18:447-59.
21. Basu S, Totty NF, Irwin MS. Akt phosphorylates the Yes-associated protein, YAP, to induce interactionwith 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003;11:11-23. (Pubitemid 36126587)
22. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, et al. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell 2008;32:803-14.
23. Dagoneau N, Goulet M, Genevieve D, Sznajer Y, Martinovic J, Smithson S, et al. DYNC2H1 mutations cause asphyxiating thoracic dystrophy and short rib-polydactyly syndrome, type III. Am J Hum Genet 2009;84:706-11.